Arthur M. Cohen & Associates LLC Sells 1,295 Shares of Edwards Lifesciences Co. (NYSE:EW)

Arthur M. Cohen & Associates LLC decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 6.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 19,458 shares of the medical research company’s stock after selling 1,295 shares during the quarter. Arthur M. Cohen & Associates LLC’s holdings in Edwards Lifesciences were worth $1,440,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC lifted its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS bought a new position in Edwards Lifesciences during the third quarter worth about $40,000. Finally, Roble Belko & Company Inc acquired a new position in Edwards Lifesciences during the fourth quarter worth approximately $46,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on EW. Citigroup raised their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Robert W. Baird decreased their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $69.77 on Friday. The firm has a 50 day moving average of $71.99 and a 200-day moving average of $71.60. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $41.15 billion, a PE ratio of 10.07, a PEG ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 earnings per share. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock worth $2,195,180 in the last ninety days. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.